Table 2.

OR (95% CI) for symptom-detected versus screen-detected invasive breast cancers for the following biomarkers

BiomarkerUnivariate models (for single biomarker)
Multivariable models* (for single biomarker)
Multivariable model (for all biomarkers)
OR (95% CI)POR (95% CI)POR (95% CI)P
ER status
    Positive1.001.001.00
    Negative2.07 (1.82-2.36)<0.0011.35 (1.15-1.59)<0.0011.28 (0.93-1.77)1.131
PR status
    Positive1.001.001.00
    Negative1.45 (1.30-1.63)<0.0011.08 (0.94-1.23)0.2740.85 (0.66-1.09)0.207
HER-2/neu immunohistochemistry score
    0 or 1+1.001.001.00
    2+1.42 (1.17-1.72)<0.0011.28 (1.04-1.58)0.0221.13 (0.83-1.54)0.433
    3+1.64 (1.37-1.97)<0.0011.07 (0.87-1.32)0.5270.88 (0.64-1.22)0.446
Ki-67
    <10%1.001.001.00
    10-30%1.57 (1.28-1.94)<0.0011.40 (1.11-1.77)0.0051.46 (1.12-1.91)0.005
    >30%3.37 (2.65-4.29)<0.0012.11 (1.57-2.85)<0.0012.24 (1.58-3.19)<0.001
  • * Risk factors–age, stage, tumor size, and nuclear grade, were included in the multivariable logistic models for each single biomarker.

  • The multivariable logistic model for all four biomarkers included ER status, PR status, HER-2/neu immunohistochemistry score, Ki-67, and age, stage, tumor size, and nuclear grade.